A first in AMD treatment: patients show significant neovascular regression

Ophthotech Corp. has announced positive results of a phase 1 clinical study evaluating E10030, a novel anti-platelet derived growth factor (anti-PDGF) combined with an anti-vascular endothelial growth factor (anti-VEGF), in wet AMD patients.
9..0
(..)
The results were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting. E10030 is an aptamer targeting PDGF, a key molecule involved in the recruitment and maturation of pericytes. Pericytes in neovascular tissue have been shown to be protective and play a major role in anti-VEGF treatment resistance. E10030 strips the pericytes from the neovascular tissue rendering it highly sensitive to an anti-VEGF attack.